At the informal meeting of the Ministers of Competitiveness (Science and Industry), held between February 7 and 9 in San Sebastian, Spain, the issues on the table were placing science at the top of the European Union agenda and showcasing its role in economic recovery, as well taking the debate on the electric vehicle to EU level.
The Ministers of Science and Innovation from Belgium, Germany, Hungary, Ireland, Latvia, Luxembourg, Poland, Portugal and Norway attended the meeting (with other delegations represented by deputy ministers), which was chaired by the Spanish Science and Innovation Minister, Cristina Gamendia, who discussed the challenges still pending for the launch of the European Research Area and the role that science can play in achieving economic recovery and growth.
On Thursday, the Director General for Science and Innovation, Montserrat Torne, explained to journalists that the informal meeting of ministers organized by the Spanish Presidency of the EU has a 'strategic' nature, since the current situation (with the Treaty of Lisbon in effect, the EU-2020 strategy and the new European Commission), 'is a good time for science to take on a significant role on the European agenda over the coming decade. It is an opportunity for the ministers to design a new roadmap towards a knowledge-based society.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze